gonadotropin-releasing hormone

(redirected from Luteinizing hormone releasing hormone)
Also found in: Medical.
Related to Luteinizing hormone releasing hormone: Luteinizing hormone releasing hormone agonist

go·nad·o·tro·pin-re·leas·ing hormone

 (gō-năd′ə-trō′pĭn-rĭ-lēs′ĭng, -trŏp′ĭn-)
n. Abbr. GnRH
A hormone produced by the hypothalamus that signals the anterior pituitary gland to begin secreting luteinizing hormone and follicle-stimulating hormone. Also called luteinizing hormone-releasing hormone.
Translations

go·nad·o·tro·pin-re·leas·ing hor·mone

n. hormona que estimula la secreción de gonadotropina.
References in periodicals archive ?
EP-100 is a targeted membrane-disrupting peptide designed to seek and destroy cancer cells that overexpress luteinizing hormone releasing hormone (LHRH) receptors on their surfaces.
The therapeutic equivalence between bilateral orchidectomy and luteinizing hormone releasing hormone (LHRH) analogs has been accepted for over 2 decades.
Steroidal modulation of the regulatory neuropeptides: luteinizing hormone releasing hormone, neuropeptide Y and endogenous opioid peptides.
Abstract: The luteinizing hormone releasing hormone agonist leuprolide acetate is used commonly to manage reproductive problems in pet birds.
The drug is a membrane-disrupting peptide (tMDP) designed to "seek and destroy" cancer cells by targeting those with excessive luteinizing hormone releasing hormone (LHRH) receptors.
Nyberg C, Hiney J, Minks J, Dees L Ethanol alters N-methyl-DL-aspartic acid-induced secretion of luteinizing hormone releasing hormone and the onset of puberty in the female rat.
3 pg/mL in castration studies evaluating luteinizing hormone releasing hormone (LHRH) agonist treatment in young males (Schmidt et al, Arch Gen Psychiatry, 2004; 61:997-1004) and in men with prostate cancer (Smith, MR, Clin Cancer Res.
EPCE100 is a targeted membraneCEdisrupting peptide (tMDP) designed to seek and destroy cancer cells that overCEexpress luteinizing hormone releasing hormone (LHRH) receptors on their surfaces.
5 mg is a new 6-month-formulation of a luteinizing hormone releasing hormone (LHRH) agonist for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer, developed by Debiopharm Group.
EPCE100 is designed to seek and destroy cancer cells that overCEexpress luteinizing hormone releasing hormone (LHRH) receptors on their surfaces.
Luteinizing Hormone Releasing Hormone Analogue Import Volume and Market Share
EP-100 is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces.

Full browser ?